Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

German Merck Identifies Pipeline Stars, Plots Course Through A Dynamic Cancer Space

Executive Summary

As questions remain over Merck KGAA's ability to retain its top line following the patent loss for its key products Rebif and Erbitux, the German company has highlighted some of its higher priority R&D programs in its "very interesting" pipeline, as well as its strategy to make the most of the assets.

Advertisement

Related Content

Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts
Interview: German Merck Set For Big "Leap" In India
Resilient US Rebif, Gonal-f Q2 Sales Allow German Merck To Up Forecast
2Q Pharma Results Preview: Pfizer, Shire, Merck KGaA, Teva, Novo Nordisk And Allergan
German Merck Aims To Lift Its UK R&D Efforts, Despite Brexit Uncertainty
Early Tecentriq OK Gives Roche/Genentech Jump On PD-L1 Bladder Cancer Market
Threshold Plummets As Merck Drops Evofosfamide For Sarcoma
Merck KGaA Returns PKU Drugs To BioMarin To Focus On Cancer
Pfizer sides with Merck KGaA on PD-L1; AZ deal out for good?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register